FLORENCE AKOUEGNON: Open Payments
NPI 1083048748 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,652 in 93 payments from 17 companies in 2025. Trend: 2023 $163 · 2024 $1,960 · 2025 $2,652
Food & beverage: $2,640Education: $12
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $374 |
| Neurocrine BioSciences, Inc. | 12 | $302 |
| Vanda Pharmaceuticals Inc. | 9 | $286 |
| Alkermes, Inc. | 9 | $262 |
| Axsome Therapeutics, Inc. | 6 | $223 |
| Teva Pharmaceuticals USA, Inc. | 5 | $188 |
| Otsuka America Pharmaceutical, Inc. | 10 | $171 |
| ABBVIE INC. | 8 | $149 |
| Lilly USA, LLC | 5 | $149 |
| Verona Pharma, Inc. | 1 | $124 |
Products named: CAPLYTA, INGREZZA, FANAPT, LYBALVI, Auvelity, AUSTEDO XR, REXULTI, VRAYLAR.
Industry payments across DE — which companies pay providers there.
